AR105010A1 - Composiciones inmunógenas - Google Patents

Composiciones inmunógenas

Info

Publication number
AR105010A1
AR105010A1 ARP160101784A ARP160101784A AR105010A1 AR 105010 A1 AR105010 A1 AR 105010A1 AR P160101784 A ARP160101784 A AR P160101784A AR P160101784 A ARP160101784 A AR P160101784A AR 105010 A1 AR105010 A1 AR 105010A1
Authority
AR
Argentina
Prior art keywords
gmma
immunogen compositions
adjuvant
immunogenic composition
purified
Prior art date
Application number
ARP160101784A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AR105010A1 publication Critical patent/AR105010A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Reivindicación 1: Una composición inmunógena que comprende (a) GMMA de Shigella sonnei purificados, (b) GMMA de Shigella flexneri purificados y (c) un adyuvante, en la que los GMMA comprenden lípido A modificado. Reivindicación 11: La composición inmunógena de cualquier reivindicación anterior, en la que el adyuvante es hidróxido de aluminio.
ARP160101784A 2015-06-16 2016-06-15 Composiciones inmunógenas AR105010A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15020097 2015-06-16

Publications (1)

Publication Number Publication Date
AR105010A1 true AR105010A1 (es) 2017-08-30

Family

ID=53442444

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101784A AR105010A1 (es) 2015-06-16 2016-06-15 Composiciones inmunógenas

Country Status (10)

Country Link
US (2) US20180169206A1 (es)
EP (2) EP3310381B1 (es)
JP (2) JP6930927B2 (es)
CN (2) CN107921116A (es)
AR (1) AR105010A1 (es)
BE (1) BE1024284B1 (es)
CA (1) CA2989242A1 (es)
ES (1) ES2952422T3 (es)
MX (1) MX2017016401A (es)
WO (1) WO2016202872A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016202872A1 (en) 2015-06-16 2016-12-22 Glaxosmithkline Biologicals Sa Immunogenic compositions
GB201712824D0 (en) * 2017-08-10 2017-09-27 Glaxosmithkline Biologicals Sa Multi-functionalized nOMV Conjugates
CA3095914A1 (en) * 2018-04-03 2019-10-10 University Of Maryland, Baltimore Enhanced shigella-enterotoxigenic e. coli multi-valent vaccine
TWI722535B (zh) * 2018-08-21 2021-03-21 美商美國禮來大藥廠 測定蛋白質或肽濃度的方法及其用途
EP3808372A1 (en) * 2019-10-17 2021-04-21 GlaxoSmithKline Biologicals S.A. Novel vaccine compositions
GB202112149D0 (en) * 2021-08-24 2021-10-06 Glaxosmithkline Biologicals Sa Shigellla vaccine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679564A (en) 1994-10-05 1997-10-21 Antex Biologics, Inc. Methods for producing enhanced antigenic campylobacter bacteria and vaccines
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB201017519D0 (en) * 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
KR20150127206A (ko) * 2013-03-14 2015-11-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 나노입자-기재 조성물
WO2014192031A1 (en) * 2013-05-31 2014-12-04 Indian Council Of Medical Research A multi-serotype outer membrane vesicles (momv) of shigellae as a novel candidate vaccine
CN103966308B (zh) 2013-12-31 2016-04-06 中国疾病预防控制中心传染病预防控制所 福氏志贺菌o-抗原3/4-o-乙酰化修饰检测试剂及其应用
CN103933559B (zh) * 2014-04-29 2016-08-17 北京智飞绿竹生物制药有限公司 志贺氏菌多价结合疫苗
WO2016012587A1 (en) * 2014-07-25 2016-01-28 Biosynth S.R.L. Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria
WO2016202872A1 (en) * 2015-06-16 2016-12-22 Glaxosmithkline Biologicals Sa Immunogenic compositions
CN110248681A (zh) 2016-11-25 2019-09-17 葛兰素史密丝克莱恩生物有限公司 nOMV-抗原缀合物及其用途

Also Published As

Publication number Publication date
CN107921116A (zh) 2018-04-17
US11986518B2 (en) 2024-05-21
EP4241851A2 (en) 2023-09-13
CN114796472A (zh) 2022-07-29
JP2018517729A (ja) 2018-07-05
JP2021167317A (ja) 2021-10-21
EP4241851A3 (en) 2023-12-06
ES2952422T3 (es) 2023-10-31
JP6930927B2 (ja) 2021-09-01
BE1024284B1 (fr) 2018-01-15
MX2017016401A (es) 2018-03-02
EP3310381A1 (en) 2018-04-25
US20180169206A1 (en) 2018-06-21
US20200384096A1 (en) 2020-12-10
BE1024284A1 (fr) 2018-01-12
CA2989242A1 (en) 2016-12-22
EP3310381B1 (en) 2023-06-07
WO2016202872A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
AR105010A1 (es) Composiciones inmunógenas
AR109139A1 (es) Método para generar aerosol
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
CL2020000927A1 (es) Método para la liberación acelerada de 1-mcp de una composición que comprende 1-mcp. (divisional solicitud 201802371)
AR125320A2 (es) Compuesto cristalino, método de preparación y composición que lo comprende
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CL2017002606A1 (es) Inhibidor de bromodominio
CL2018003504A1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos.
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
BR112017002370A2 (pt) indóis para uso na infecção pelo vírus da gripe
UY38403A (es) Moduladores de la alfa-1 antitripsina
AR111304A1 (es) Métodos para sintetizar un inhibidor de mcl-1
AR106683A1 (es) FOSFORAMIDITA DE AGRUPACIÓN DE GalNAc
MX2017002954A (es) Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benz oxazol.
CO2018008304A2 (es) Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
CL2020000879A1 (es) Análogos de saponina de triterpeno.
CL2019001337A1 (es) Formulaciones farmacéuticas.
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
BR112018073100A2 (pt) material luminescente
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
CL2016002089A1 (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO2022009068A2 (es) Composición para la inhibición de la producción de hmf que comprende disacárido de alulosa

Legal Events

Date Code Title Description
FB Suspension of granting procedure